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Abstract
Next-generation sequencing technologies have been and continue to be deployed in clinical
laboratories, enabling rapid transformations in genomic medicine. These technologies have
reduced the cost of large-scale sequencing by several orders of magnitude, and continuous
advances are being made. It is now feasible to analyze an individual's near-complete exome or
genome to assist in the diagnosis of a wide array of clinical scenarios. Next-generation sequencing
technologies are also facilitating further advances in therapeutic decision making and disease
prediction for at-risk patients. However, with rapid advances come additional challenges involving
the clinical validation and use of these constantly evolving technologies and platforms in clinical
laboratories. To assist clinical laboratories with the validation of next-generation sequencing
methods and platforms, the ongoing monitoring of next-generation sequencing testing to ensure
quality results, and the interpretation and reporting of variants found using these technologies, the
American College of Medical Genetics and Genomics has developed the following professional
standards and guidelines.
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A. INTRODUCTION
Sequencing technologies have evolved rapidly over the past 5 years. Semi-automated Sanger
sequencing has been used in clinical testing for many years and is still considered the gold
standard. However, its limitations include low throughput and high cost, making multigene
panels laborious and expensive. Recent technological advancements have radically changed
the landscape of medical sequencing. Next-generation sequencing (NGS) technologies
utilize clonally amplified or single molecule templates, which are then sequenced in a
massively parallel fashion. This increases throughput by several orders of magnitude. NGS
technologies are now being widely adopted in clinical settings. Three main levels of
analysis, with increasing degrees of complexity, can now be performed via NGS: disease-
targeted gene panels, exome sequencing (ES), and genome sequencing (GS). All have
advantages over Sanger sequencing in their ability to sequence massive amounts of DNA,
yet each also has challenges for clinical testing.
A.1. Disease-targeted gene panels
Disease-targeted gene panels interrogate known disease-associated genes. Focusing on a
limited set of genes allows greater depth of coverage for increased analytical sensitivity and
specificity. Greater depth of coverage increases the confidence in heterozygous calls and the
likelihood of detecting mosaicism or low level heterogeneity in mitochondrial or oncology
applications. Furthermore, because only genes with an established role in the targeted
disease are sequenced, the ability to interpret the findings in a clinical context is greater.
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Follow-up Sanger sequencing or an alternative technology can be used to fill gaps in the
NGS data for regions showing low coverage (e.g., GC-rich or repetitive regions), which
improves clinical sensitivity of the assay. Targeting fewer genes also allows the laboratory
to use desktop sequencers and run more patient samples per instrument cycle (barcoding and
pooling) compared with ES/GS. The amount of data and storage requirements are also more
manageable.
A.2. Exome sequencing
ES attempts to cover all coding regions of the genome. The exome is estimated to comprise
~1-2% of the genome, yet contains ~85% of recognized disease-causing mutations
(Majewski et al. 2011). Presequencing sample preparation is required to enrich the sample
for the targeted coding regions. Current estimates of exome coverage through NGS are
between 90 and 95% (Cirulli et al. 2010). At this time enrichment is performed by in-
solution hybridization methods. However, certain regions of the exome are still not
amenable to this method of enrichment and NGS due to sequence complexity. ES is used for
detecting variants in known disease-associated genes as well as for the discovery of novel
gene-disease associations. Gene discovery has historically been limited to research
laboratories. This is now changing with the ability to identify novel disease-gene candidates
in the clinical laboratory, although further studies, often in collaboration with research
laboratories, are required to prove the association. Coverage and cost of ES will be between
those of targeted gene panels and GS. One strategy some clinical laboratories are adopting is
to perform ES but proceed with the interpretation of only genes already known to be
associated with disease. If no mutation that can explain the patient's symptoms is identified,
the data can be reanalyzed for the remaining exome to potentially identify new disease-gene
associations. In a study from the National Institutes of Health (NIH) for rare and ultrarare
disorders, ES provided a diagnosis in nearly 20% of cases (Gahl et al. 2012). However,
because the depth of coverage for an exome is not uniform, the analytical sensitivity for ES
may be lower than the sensitivity for most targeted gene panels, given that a substantial
number of exons in known disease-associated genes may lack sufficient coverage to make a
sequence call. Although Sanger sequencing is commonly used to fill in missing content in
disease-targeted test panels, the scope of ES makes this strategy impractical, expensive, and
rarely used. Analytical specificity may also be compromised with less depth of coverage,
requiring more Sanger testing to prevent false-positive (FP) variant calls.
A.3. Genome sequencing
GS covers both coding and noncoding regions. One advantage of GS is that presequencing
sample preparation is straightforward, not requiring PCR or hybridization enrichment
strategies for targeted regions. Due to limitations in the interpretation of noncoding variants,
coding regions are often analyzed initially. If causative mutations are not found, data can
then be reanalyzed to look for regulatory variants in noncoding regions that may affect
expression of disease-associated genes. Data can also be examined for copy-number variants
(CNVs) or structural variants that may either be outside of the coding regions or more easily
detected using GS due to increased quantitative accuracy. GS is currently the most costly
technology with the least average depth of coverage, although these limitations are likely to
diminish in the future.
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This document describes the standards and guidelines for clinical laboratories performing
NGS for assessment of targeted gene panels, the exome, and the genome. Given the rapid
pace with which this area of molecular diagnostics is advancing, this document attempts to
cover issues essential for the development of any NGS test. It does not address specific
technologies in detail and may not cover all issues relevant to each test application or
characteristics unique to a specific platform. For example, this document does not focus on
testing related to somatic variation and other mixed populations of cells, RNA applications
of NGS, or the detection of circulating fetal DNA, and therefore additional considerations
specific to these applications may be required.
B. OVERVIEW OF NGS
NGS involves three major components: sample preparation, sequencing, and data analysis
(as illustrated in Figure 1). The process begins with extraction of genomic DNA from a
patient sample, and some approaches (e.g., targeted panels and ES) will include enrichment
strategies to focus on a subset of genomic targets. A set of short DNA fragments (100-500
base pairs) flanked by platform-specific adapters is the required input for most currently
available NGS platforms. A series of processing steps is necessary to convert the DNA
sample into the appropriate format for sequencing. Multiple commercial sequencing
platforms have been developed, all of which have the capacity to sequence millions of DNA
fragments in parallel. Differences in the sequencing chemistry of each platform result in
differences in total sequence capacity, sequence read length, sequence run time, and final
quality and accuracy of the data. These characteristics may influence the choice of platform
to be used for a specific clinical application. When the sequencing is complete, the resulting
sequence reads are processed through a computational pipeline designed to detect DNA
variants. Commonly used sample preparation methods, sequencing platforms, and steps in
data analysis are briefly described below.
B.1. Sample preparation
NGS may be performed on any sample type containing DNA, as long as the quality and
quantity of the resulting DNA are sufficient. The laboratory should specify the required
sample type and quantity based on their validation data. Given the complexity of the
procedures and likelihood of manual steps, processes to prevent sample mix-up or to
confirm final results must be employed as discussed in subsequent sections.
B.2. Library generation
Library generation is the process of creating random DNA fragments, of a certain size range,
that contain adapter sequences on both ends. The adapters are complementary to platform-
specific PCR and sequencing primers. Fragmentation of genomic DNA can be achieved
through multiple methods, each having strengths and weaknesses. For most applications/
platforms, PCR amplification of the library is necessary before sequencing.
B.3. Barcoding
Barcoding refers to the molecular tagging of samples with unique sequence-based codes,
typically consisting of three or more base pairs. This enables pooling of patient samples,
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thereby reducing the per-sample processing cost. The number of samples that can be pooled
will depend on the desired coverage of the region to be sequenced. Barcodes can be part of
the adapter or can be added as part of a PCR enrichment step that is included in most
protocols.
B.4. Target enrichment
Unless GS is performed, the genes or regions of interest must be isolated before sequencing.
The targets can range from a relatively small number of genes (e.g., all genes associated
with a specific disease) to the entire exome (all known protein-coding exons). Target
enrichment approaches can be divided into multiplexed PCR-based methods (single or
multiplex PCR or droplet PCR) and solid or in-solution oligonucleotide hybridization-based
methods. Hybridization-based capture can be used for ES but PCR-based approaches
currently do not scale to that size. Strategies for target enrichment are reviewed in
Mamanova et al. 2010.
B.5. Sequencing platforms
Currently available commercial platforms are based upon the ability to perform many
parallel chemical reactions in a manner that allows for the individual products to be
analyzed. Chemistries include sequencing by synthesis or sequencing by ligation with
reversible terminators, bead capture, and ion sensing (Glenn 2011). Each platform has
specific parameters relevant to the laboratory and test requirements including instrument
size, instrument cost, run time, read length, and cost per sample.
B.6. Data analysis
Given the huge amount of sequence data produced by NGS platforms, the development of
accurate and efficient data handling and analysis pipelines is essential. This requires
extensive bioinformatics support and hardware infrastructure. NGS data analysis can be
divided into four primary operations: base calling, read alignment, variant calling, and
variant annotation. Base calling is the identification of the specific nucleotide present at each
position in a single sequencing read; this is typically integrated into the instrument software
given the technology-specific nature of the process. Read alignment involves correctly
positioning short DNA sequence reads (often 50-400 base pairs) along the genome in
relation to a reference sequence. Variant calling is the detection of the DNA variants in the
sequence analyzed as compared with a reference sequence. The accuracy of identifying
variants greatly depends on the depth of sequence coverage; increased coverage improves
variant calling. Because some regions may have low sequence coverage, it is important to
track positions where there is absent data or an ambiguous call, enabling test limitations to
be defined. Variant annotationadds information about each variant detected. For example,
annotation pipelines will determine whether a variant is within or near a gene, where the
variant is located within that gene (e.g.,untranslated region, exon, intron), and whether the
variant causes a change in an amino acid within the encoded protein. Ideally, the annotation
will also include additional information that facilitates interpretation of its clinical
significance. This information may include the presence of the variant in certain databases,
the degree of evolutionary conservation of the encoded amino acid, and a prediction of
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whether the variant is pathogenic due its potential impact on protein function using in silico
algorithms.
C. TEST ORDERING
In the traditional genetic testing setting for disease diagnosis, the ordering physician's role is
to generate a differential diagnosis based on clinical features, family history, and physical
examination. Genetic test(s) may be ordered to confirm or exclude a diagnosis. Laboratories
perform the ordered genetic test(s) and report the presence of all potentially deleterious
variants in the gene(s) analyzed as well as the test methods and performance parameters of
each test. Targeted NGS panels represent the logical extension of current sequencing tests
for genetically heterogeneous disorders. By limiting the content of the test to just the regions
relevant to a given disease, the resulting data usually have higher analytical sensitivity and
specificity for detecting mutations. In addition, the laboratory is more likely to employ
approaches to ensure complete coverage of the targeted regions such as performing Sanger
sequencing for those areas with inadequate coverage. Finally, a more thorough analysis and
interpretation of the data to account for all known variation previously associated with the
disease may be performed. Targeted NGS panels may also conform more readily to current
models of reimbursement for molecular diagnostic tests. Therefore, it may be more
appropriate to initiate testing with disease-targeted panels before proceeding to ES or GS
approaches until the technical and interpretative quality of ES/GS reaches that of disease-
targeted testing.
By contrast, the use of ES or GS enables a broader hypothesis-free approach to testing the
patient. Consequently, these tests require more collaboration between the laboratory and
health-care providers to enable appropriate data interpretation. ES and GS approaches are
currently being utilized primarily for cases in which disease-targeted testing is unavailable
or was already conducted and did not explain the patient's phenotype. However, this is likely
to change in the future. Performing an ES or GS test but then initially restricting the analysis
to a disease-associated set of genes based on the patient's clinical indications may also be
considered. If this is done, the laboratory needs to state the relevant parameters (e.g.,
coverage of the specific genes) in the patient's report, allowing the physician to compare the
performance of the ES/GS test to an available disease-specific panel test. Careful
consideration for the potential impact of incidental findings, which may include carrier
status for recessive diseases, must also be weighed given the context in which data are
analyzed and returned to the patient. The laboratory director is responsible for describing
both the advantages and limitations of their test offerings so that the health-care provider can
make an informed decision.
Regardless of the approach employed, it is recommended that referring physicians provide
detailed phenotypic information to assist the laboratory in analyzing and interpreting the
results of testing. This step is a necessity for ES and GS to enable appropriate filtering
strategies to be employed. It is also highly recommended for large disease panel testing,
given the diversity of genes and subphenotypes that may be included in a test panel. The
ability for laboratories to prioritize variants for further consideration or likely relevance may
be dependent on the constellation of existing symptoms and findings in the patient and
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future clinical evaluation in collaboration with the healthcare providers. Furthermore, the
ability to increase knowledge of variant significance is greatly aided by laboratories
receiving and tracking patient phenotypes and correlating them with genotypes identified.
D. UPFRONT CONSIDERATIONS FOR TEST DEVELOPMENT
D.1. Test content
The factors relevant to test ordering described above also have an impact on the laboratory's
strategy for test development. Test development costs, analytical sensitivity and specificity,
and analysis complexity are important factors that must be evaluated when considering
development of NGS services.
D.1.1. Disease-targeted gene panels—It is recommended that the selection of genes
and transcripts to be included in clinical disease-targeted gene panels using NGS be limited
to those genes with sufficient scientific evidence for a causative role in the disease.
Candidate genes without clear evidence of a disease association should not be included in
these disease-targeted tests. If a disease-targeted panel contains genes for multiple
overlapping phenotypes, laboratories should consider providing a physician the option for
restricting analysis to a subpanel of genes associated to the subphenotype (e.g., hypertrophic
cardiomyopathy genes within a broad cardiomyopathy gene panel) to minimize the number
of variants of unknown significance detected. Laboratories should also consider the
expected number of detected variants and account for the time and expertise required for
their evaluation. As a guide, the number of variants with potential clinical relevance will be
approximately proportional to the size of the target region being analyzed.
D.1.2. Exome and genome sequencing—ES is a method of testing the RNA-coding
exons and flanking splice sites of all recognized genes in the human genome. By contrast,
GS attempts to sequence the entire three billion bases of the human genome. The ability to
target the exome in ES is based on capture of the exome using a variety of reagent kits
typically sold by commercial suppliers (see Clark et al. 2011 for a review). Laboratories
should consider the differences between the commercially available reagents and be aware
of refractory regions in each design. No exome capture method is fully efficient; therefore,
laboratories must describe the method used and the capture efficiency expected based on
their validation studies. Although GS is not dependent on capture limitations, not all regions
of human DNA can be accurately sequenced with current methods (e.g., repetitive DNA),
and therefore limitations of content, including limitations on assessing known disease-
associated loci such as triplet repeat expansion diseases, must be described. Furthermore, if
ES testing is marketed as a disease-targeted test, the coverage of high-contributing disease
genes and variants, as determined during test validation, should be clearly noted in material
accessible during test ordering as well as prominently noted on reports.
For targeted testing of diseases with significant genetic heterogeneity, ES/GS strategies may
be more efficient, but limitations in gene inclusion and coverage must be clearly noted if
such a test is marketed for a specific disease indication. If disease-associated variants are
expected to occur beyond exonic regions (e.g., regulatory, copy-number or structural
variation), the test design strategy should include approaches to detect these types of
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variation. Laboratories may consider supplementing an ES assay with complementary assays
to be able to detect all types of disease-associated variants. Alternatively, it must be clearly
stated that these types of variants will not be detected. Inclusion of these variants may
require supplementation of the standard assay or the use of companion technologies to
improve the sensitivity of the test (e.g., adding capture probes designed for nonexonic
regions to a ES test, Sanger sequencing to fill in low-coverage areas, molecular or
cytogenetic methods to detect CNVs and structural variants).
D.2. Choice of sequencer and sequencing methods
In choosing a sequencer, the laboratory must carefully consider the size of the sequenced
region, required depth of coverage, projected sample volume, turnaround time requirements,
and costs. These considerations are important for a decision to invest in a desktop or
standalone sequencer which has a substantial difference in sequencing capacity. For
example, long read lengths may be useful for certain applications, such as analysis of highly
homologous regions. Short-read technologies may be sufficient for other applications. As
maximum read length is platform dependent, the test design, choice of platform, and choice
of read length should be based on the type of variation that must be detected.
General sequencing modes include single-end sequencing (genomic DNA fragments are
sequenced at one end only) and paired-end sequencing (both ends are sequenced). Paired-
end sequencing increases the ability to map reads unambiguously, particularly in repetitive
regions (see section D.5.), and has the added advantage of increasing coverage and
stringency of the assay as bidirectional sequencing of each DNA fragment is performed. A
variation of paired end sequencing is mate-pair sequencing, which can be useful for
structural variant detection.
Support for therapeutic decision making and targeted NGS gene panels in a prenatal setting
requires quick turnaround as compared with other less time-sensitive applications. High-
throughput instruments can reduce per-sample cost, but only if sufficient numbers of tests
would be ordered. For disorders that require detection of variants below germline
heterozygosity, such as somatic mutation testing in tumors and detection of heteroplasmic
mitochondrial variants, approaches should be taken that achieve higher coverage should be
taken. In addition, non-Sanger strategies to confirm low-level variation may be necessary,
either through duplicate testing to increase confidence or through other complementary
methods.
D.3. Choice of data analysis tools
D.3.1. Base calling—Each NGS platform has specific sequencing biases that affect the
type and rates of errors made during the data-generation process. These can include signal-
intensity decay over the read and erroneous insertions and deletions in homopolymeric
stretches (Ledergerber and Dessimoz, 2011). Base-calling software that accounts for
technology-specific biases can help address platform-specific issues. The best practice is to
utilize a base-calling package that is designed to reduce specific platform-related errors.
Generally, an appropriate, platform-specific base-calling algorithm is embedded within the
sequencing instrument. Each base call is associated with a quality metric providing an
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evaluation of the certainty of the call. This is usually reported as a Phred-like score
(although some software packages use a different quality metric and measure slightly
different variables).
D.3.2. Read alignment—Various algorithms for aligning reads have been developed that
differ in accuracy and processing speed. Depending upon the types of variations expected,
the laboratory should choose one or more read-alignment tools to be applied to the data.
Several commercially available or open-source tools for read alignment are available that
utilize a variety of alignment algorithms and may be more efficient for certain types of data
than for others (Li and Homer 2010). Proper alignment can be challenging when the
captured regions include homologous sequences but is improved by longer or paired-end
reads. In addition, it is suggested that alignment to the full reference genome be performed,
even for exome and disease-targeted testing, to reduce mismapping of reads from off-target
capture, unless appropriate methods are used to ensure unique selection of targets.
D.3.3. Variant calling—The accuracy of variant calling depends on the depth of sequence
coverage and improves with increasing coverage. The variant caller can differentiate
between the presence of heterozygous and homozygous sequence variations on the basis of
the fraction of reads with a given variant. It can also annotate the call with respect to proper
genome and coding sequence nomenclature. Most variant-calling algorithms are capable of
detecting single or multiple base variations, and different algorithms may have more or less
sensitivity to detect insertions and deletions (in/dels), large CNVs, and structural
chromosomal rearrangements (e.g., translocations, inversions). Local realignment after
employing a global alignment strategy can help to more accurately call in/del variants
(DePristo et al. 2012). Large deletions and duplications are detected either by comparing
actual read depth of a region to the expected read depth or through paired-end read mapping
(independent reads that are associated to the same library fragment). Paired-end and mate-
pair (joined fragments brought from long genomic distances) mapping can also be used to
identify translocations and other structural rearrangements.
D.3.4. File formats—Many different formats exist for the export of raw variants and their
annotations. Any variant file format must include a definition of the file structure and the
organization of the data, specification of the coordinate system being used (e.g., the
reference genome to which the coordinates correspond, whether numbering is 0-based or 1-
based, and the method of numbering coordinates for different classes of variants), and the
ability to interconvert to other variant formats and software. If sequence read data are
provided as the product of an NGS test, they should conform to one of the widely used
formats (e.g., “.bam” files for alignments, “.fastq” files for sequence reads) or have the
ability to be readily converted to a standard format. Although there is currently no official
gold standard, a de facto standard format that has emerged is the variant call format (.vcf)
used by the 1000 Genomes Project. This structured-text file format conveys meta-
information about a given file and specific data about arbitrary positions in the genome. It
should be noted that the .vcf file format is typically limited to variant calls, and many
advocate the inclusion of reference calls in the .vcf format to distinguish the absence of data
from wild-type sequence. At the time of this publication, an effort led by the Centers for
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Disease Control and Prevention is currently under way to develop a consensus gVCF file
format.
D.4. Variant filtering
In traditional disease-targeted testing, the number of identified variants is small enough to
allow for the individual assessment of all variants in each patient, once common benign
variations are curated. However, ES identifies tens of thousands of variants, while GS
identifies several million, making this approach to variant assessment impossible. A filtering
approach must be applied for ES/GS studies, and laboratories may even need to employ
auto-classification strategies for very large disease-targeted panels. Regardless of the
approach, laboratories should describe their methods of variant filtering and assessment,
pointing out their limitations.
D.4.1. Disease-targeted panels—As Mendelian disease-targeted panels increase in
gene content, laboratories may need to develop auto-classification tools to filter out common
benign variants from rare highly penetrant variants. Sources of broad population frequencies
that can be used for auto-classification of benign variation include dbSNP (http://
www.ncbi.nlm.nih.gov/projects/SNP), the NHLBI Exome Sequencing Project
(evs.gs.washington.edu/EVS), and the 1000 Genomes Project (http://www.
1000genomes.org). The frequency cutoff that a laboratory employs for this step will depend
on the maximum frequency of a single disease variant. The frequency is based on disease
prevalence, inheritance pattern, and mutation heterogeneity. However, frequency cutoffs
should be higher than the theoretical maximum to account for statistical variance in those
population estimates due to the control sample size; the possibility of undocumented
reduced penetrance; and the possible inclusion of individuals who have not been
phenotyped, who have asymptomatic or undiagnosed disease, or who have a known disease.
Furthermore, laboratories should not simply use currently available disease-specific
databases for directly filtering variants to determine which will be reported as disease
causing. Few, if any, variant databases are curated to a clinical grade with strict, evidence-
based consensus assessment of supporting data. It is well known that many databases
contain misclassified variants, particularly benign variation misclassified as disease causing
(Bell et al. 2011). In addition, most Mendelian diseases have a large percentage of variants
that are private (unique to families), requiring a robust process for assessing novel variation.
Published guidelines contain further recommendations on the classification of sequence
variants (Richards et al. 2008).
D.4.2. Exome and genome sequencing—In the analysis of ES/GS, the assumptions
that causative mutations for Mendelian disorders will be rare and highly penetrant must be
made (Majewski et al. 2011). However, the laboratory must apply additional strategies to
variant and gene filtration beyond this assumption. Successfully identifying the molecular
basis for a rare disorder may depend on the strategy employed, such as choosing appropriate
family members for comparison, given a suspected mode of inheritance. The strategies
employed will depend on the indication for testing and the intent to return incidental
findings. The ultimate goal is to reduce the number of variants needing examination by a
skilled analyst. Variants may be included or excluded based on factors including: presence
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in a disease candidate gene list, presumed inheritance pattern in the family (e.g., biallelic if
recessive), likelihood of consanguinity in the parents (e.g., homozygous variants), mutation
types (e.g., truncating, copy number), presence or absence in control populations,
observation of de novo occurrence (if the phenotype is sporadic in the context of a dominant
disorder), gene expression pattern, algorithmic scores for in silico assessment of protein
function or splicing impact, and biological pathway analysis. The choice of filtering
algorithm design may differ across case types and requires a high level of expertise in
genetics and molecular biology. This expertise should include a full understanding of the
limitations of the databases against which the patients results are being filtered and the
limitations of both the sequencing platform and multiple software applications being used to
generate the variants being evaluated. Individuals leading these analyses should have
extensive experience in the evaluation of sequence variation and evidence for disease
causation, as well as an understanding of the molecular and bioinformatics pitfalls that could
be encountered.
Laboratories must balance overfiltering, which could inadvertently exclude causative
variants, with underfiltering, which presents too many variants for expert analysis. A
stepwise approach may be necessary, using a first pass to identify any clear and obvious
causes of disease. If needed, filtering criteria can be subsequently reset to provide an
expanded search resulting in a larger number of variants for evaluation. Once the data
analysis approach for each patient has been set, laboratories must provide ordering health-
care providers documentation of their general and patient-specific processes. There should
be clear documentation of the basic steps taken to achieve the reported results on each
patient.
D.5. Sequencing regions with homology
Homologous sequences such as pseudogenes pose a challenge for all short-read sequencing
approaches. Cocapture cannot be avoided for targeted NGS when a hybridization-based
enrichment method is used. The limited length of NGS sequence reads can lead to FP
variant calls when reads are incorrectly aligned to a homologous region, but also to false-
negative (FN) results when variant-containing reads align to homologous loci. Therefore, the
laboratory must develop a strategy for detecting disease-causing variants within regions with
known homology. These strategies might include local realignment after employing a global
alignment strategy, which can help with some types of misalignment due to homologous or
repetitive sequences. In addition, paired-end sequencing may partially remedy this problem
because reads can usually be mapped uniquely if one of the paired ends maps uniquely.
Alternatively, if there is enough depth of coverage and relaxed allelic fraction ratios allow
reads to be mapped to both homologous regions, then correct variant mapping can be
elucidated with Sanger confirmation using uniquely complementary primer pairs.
D.6. Companion technologies and result confirmation
Result confirmation is essential when the analytic FP rate is high or not yet well established,
particularly as in ES and GS approaches. Confirmation can also be used to confirm sample
identity, which is critical when laboratory workflows are complex and not fully automated.
FP rates for most NGS platforms in current use are appreciable, and therefore it is
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recommended that all disease-focused and/or diagnostic testing include confirmation of the
final result using a companion technology. This recommendation may evolve over time as
technologies and algorithms improve. However, laboratories must have developed extensive
experience with NGS technology and be sufficiently aware of the pitfalls of the technologies
they are using and the analytical pipelines developed before deciding that result
confirmation with orthogonal technology can be eliminated, particularly for in/del variants,
which are notably more challenging to detect and define correctly. Extensive validation of
variant detection using all types of variation and across all variations in assay performance is
necessary before confirmation can be eliminated or reduced. Sanger sequencing is most
often employed as the orthogonal technology for germline nuclear DNA testing. For testing
involving low-percentage variants such as the detection of somatic variants from tumor
tissue, heteroplasmic mitochondrial variants, and germline mosaic variants, other
approaches such as replicate testing may be necessary.
Sanger sequencing can also be used to “fill in” missing data from bases or regions that are
supported by an insufficient number of reads to call variants confidently. It may be
acceptable to report results without complete coverage at a predefined minimum for some
tests, such as for ES/GS and certain broad gene-based panels (e.g., large-scale recessive-
disease carrier testing). The laboratory director has discretion to judge the need for Sanger
sequencing to fill in missing areas of a test. However, it is currently recommended that all
disease-focused testing of high-yield genes include complete coverage in each patient tested.
It is also important, particularly for targeted gene panels, that the laboratory's test report
include information about regions/genes that were not covered in a given sample.
It is recommended that the companion assays required for this step be developed or planned
for in advance of their need, to ensure reasonable turnaround times. Projected turnaround
times should take into account the time required for using these companion technologies. In
testing environments where confirmation of all results may not be possible before initial
reporting (e.g., certain lower-risk incidental findings from ES/GS studies such as
pharmacogenetic alleles for drugs not under consideration for the patient), it is
recommended that laboratories clearly state the need for follow-up confirmatory testing. For
example, the report could state “The following results have not been confirmed by an
alternate method or replicate test, and the reported accuracy of variants included in this
report is ~x% (or ranges from x to y%). If these results will be used in the care of a patient,
the need for requesting confirmation must be weighed against the risk of an erroneous
result.”
E. TEST DEVELOPMENT AND VALIDATION
E.1. General considerations
Various combinations of instruments, reagents, and analytical pipelines may be used in tests
involving NGS. Some may in the future be approved by the US Food and Drug
Administration (FDA) and be available through a commercial source. Other components
may be labeled “for investigational use only,” “for research use only,” or as an “analyte-
specific reagent.” In some instances, components are commercially available but must then
be validated by the clinical laboratory for use as a diagnostic tool. Alternatively, components
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can be combined by the laboratory into a test and then validated within the laboratory for
use as a diagnostic tool. Depending on the intended clinical application of the products, each
may be subject to different levels of validation. Currently, any laboratory test that is not
exclusively based on a FDA-approved assay is considered to be part of a laboratory
developed test and will require a full validation (instead of a verification) (Jennings et al.
2009). The availability of validation data from outside sources may influence the extent to
which a laboratory independently validates the products. However, the laboratory director
must conduct an appropriate validation of each test offered in the clinical setting. The entire
test development and validation process is shown in Figure 2.
E.1.1. Test development and platform optimization—Once the individual
components of the testing process (library preparation method, target capture if applicable,
sequencer and analysis tools) have been chosen, iterative cycles of performance
optimization typically follow until all assay conditions as well as analysis settings are
optimized. During this phase, if pooling of samples is planned, the laboratory should also
determine the number of samples that can be pooled per sequencing run to achieve the
desired coverage level and establish baseline cost and turnaround time projections. Due to
the complexity of the data analysis process and the challenges surrounding correct mapping
of short sequence reads, the laboratory should establish performance of the variant calling
pipeline by analyzing data containing known sequence variants of various types (e.g., single-
nucleotide variants, small in/dels, large CNVs, structural variants). The use of synthetic
variants can help to create a rich set of testing data that can be used to compare various tools
and to optimize settings and thresholds. A protocol for the entire workflow must be
established and adhered to before proceeding to test validation. Optimization must include
all sample types that will be evaluated in clinical practice (e.g., whole blood, saliva,
formalin-fixed paraffin-embedded tissue).
E.1.2. Test validation—Once assay conditions and pipeline configurations have been
established, the entire test should be validated in an end-to-end manner on all permissible
sample types. Assay performance characteristics including analytical sensitivity and
specificity (positive and negative percent agreement of results when compared with a gold
standard) as well as the assay's repeatability (ability to return identical results when multiple
samples are run under identical conditions) and reproducibility (ability to return identical
results under changed conditions) need to be established (Chen et al. 2009; Jennings et al.
2009; Mattocks et al. 2010; Gargis et al. 2012). Because NGS technologies are still
relatively new and multiple options exist for every step in the workflow, the scope of
validation depends on the degree to which analytic performance metrics have already been
established for the chosen combination of sample preparation, sequencing platform, and data
analysis method. The first test developed by a laboratory may therefore carry a higher
“validation burden” than subsequent tests developed on an established platform using the
same basic pipeline design. In practice this may entail sequencing a larger number of
samples to cover sufficient numbers of all variant types. In subsequent test validations,
fewer samples of each type may be required. To determine the analytic validity of a test, the
laboratory should utilize well-characterized reference samples for which reliable Sanger
sequencing data exist. These samples should ideally be a renewable resource, which can
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then be used to establish baseline data with which future test modifications can be
compared. See section F.7 for a more detailed discussion. Reference samples do not need to
contain specific pathogenic variants because they are used to assess the overall ability of a
test to detect a type of variant, and the clinical significance of the variant has little bearing
on its detectability (analytic validity).
In addition to the general approaches described above, there are also content- and
application-specific issues that must be addressed as noted below for targeted panels and
exome and genome testing. For disease-specific targeted gene panels, test validations must
include unique gene- and disease-specific aspects. It is critical to include common
pathogenic variants in the validation set to ensure that the most common causes of disease
are detectable, given that sequence-specific context can affect the detection of a variant. In
addition, issues related to accurate sequencing of highly homologous regions need to be
addressed when one or more genes within the test have known pseudogenes or other
homologous loci.
For ES and GS, the focus of validation is shifted more toward developing metrics that define
a high-quality exome/genome such as the average coverage across the exome/genome and
the percentage of bases that meet a set minimum coverage threshold. Validation of ES/GS
should include evaluation of a sample that was well analyzed using another platform. There
are several samples available for this purpose that have previously been sequenced using
Sanger methods. See section F.7 for a more detailed discussion. For GS, the sample could be
one that was previously analyzed using a high-density single-nucleotide polymorphism
(SNP) array. However, this approach is less useful for ES because most of the SNPs on
commercially available high-density SNP arrays are not in regions targeted by ES capture
kits. An evaluation of the concordance of SNPs identified as compared with the reference
should be made for either ES or GS (some laboratories have used 95-98% concordance as
the minimum acceptable level).
In addition, validation of ES and GS should include sequencing a variety of samples
containing previously identified variants. This part of the validation process is identical to
what is recommended for targeted tests and should establish analytical performance for a
wide variety of variants and variant types to ensure maximum confidence in the ability of
the test to identify rare and novel variants. The samples should be blinded and subjected to
the entire end-to-end test protocol, including the bioinformatics pipeline that will be used for
the ES/GS test. Samples should be selected that represent the full spectrum of mutation
types to be analyzed.
E.1.3. Platform validation—Performance data across all tests developed by a laboratory
with the same basic platform design can be combined to establish a cumulative “platform”
performance. By maximizing the number and types of variants tested across a broad range of
genomic regions, confidence intervals can be tightened. Because the size of NGS tests make
validation of every base impossible, this approach enables extrapolation of performance
parameters to novel variant discovery within the boundaries of the established confidence.
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E.1.4. Quality management—Finally, the laboratory must develop quality control (Q/C)
measures and apply these to every run. These can vary depending on the chosen methods
and sequencing instrument but typically include measures to identify sample preparation
failures as well as measures to identify failed sequencing runs. The laboratory must also
track sample identity throughout the testing process, which is especially important given that
NGS testing commonly entails pooling of barcoded samples. Proficiency testing (PT)
protocols must also be established and executed periodically according to Clinical
Laboratory Improvement Amendments (CLIA) regulations.
E.2. Data analysis optimization
Analysis of data generated on NGS platforms is complex and typically requires a multistage
data handling and processing pipeline. Given the use of separate tools for data analysis,
which are independent of the wet-laboratory steps and the high likelihood of laboratory
customizations of these data analysis tools, it is recommended that the analytical pipelines
be validated separately during initial test development. Later the pre-validated pipeline can
then be included in each end-to-end test validation, which includes both the wet-laboratory
steps and the analytical pipeline. If using commercially developed software, the laboratory
should make all attempts to document any validation data provided by the vendor, but the
laboratory must also perform an independent validation of the tool.
The laboratory must determine the parameters and thresholds necessary to determine
whether the overall sequencing run is of sufficient quality to be considered successful. This
may include analyses at intermediate points during the sequencing run as well as at the
completion of the run (e.g., real-time error rate, percentage of target captured, percentage of
reads aligned, fraction of duplicate reads, average coverage depth, range of insert-size, etc).
In addition, the laboratory should set and track thresholds for coverage to ensure sufficient
coverage is achieved for variant calling, as well as allelic fraction, which influences
analytical sensitivity and specificity. Note that NGS variant calling tools apply default
thresholds, which may have to be optimized to enhance analytic performance. In addition,
the laboratory must establish that the analytical pipeline can accurately track sample
identity, particularly if barcoding is used.
E.2.1. Coverage—Generally, variant calls are more reliable as coverage increases, and for
ES/GS when trios are sequenced. Low coverage increases the risks of missing variants
(FNs) and assigning incorrect allelic states (zygosity), especially in the presence of
amplification bias, and decreases the ability to effectively filter out sequencing artifacts,
leading to FPs. Laboratories should establish a minimum coverage threshold necessary to
detect variants based on their diagnostic approach (e.g., only proband sequenced, proband
plus parents sequenced for ES/GS) and report analytical performance related to the
minimum threshold that is guaranteed for the test. For the detection of germline
heterozygous variants, some laboratories use 10-20X as a minimum for covering all bases of
a targeted panel. For ES and GS testing, it may be more useful to track minimum mean
coverage as well as the percentage of bases that reach an absolute minimum threshold. For
example, a laboratory may ensure that ES reaches a minimum mean coverage of 100X for
the proband and 90-95% of bases in the laboratory's defined target reach at least 10X
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coverage. A lower threshold of 70X might be used when trios are sequenced. For GS, a
laboratory may ensure that the assay reaches a minimum mean coverage of 30X. Higher
coverage, as well as additional variant calling parameters, is required for the detection of
variants from mixed or mosaic specimens (e.g., somatic tumor samples with a low
percentage of tumor cells, mitochondrial heteroplasmy, germline mosaicism). It is also
important to note that minimum coverage is highly dependent on many aspects of the
platform and assay including base-call error rates, quality parameters such as how many
reads are independent versus duplicate, and other factors such as analytical pipeline
performance. Therefore, it is not possible to recommend a specific minimum threshold for
coverage, and laboratories will need to choose minimum coverage thresholds in accordance
with total metrics for analytical validation.
E.2.2. Allelic fraction and zygosity—Germline heterozygous variants are expected to
be present in 50% of the reads. However, amplification bias and low coverage can lead to a
wider range. Laboratories must determine allelic fraction ranges to (i) distinguish true calls
from FP calls, which typically have a low allelic fraction, and (ii) assign zygosity. The
chosen parameters may be influenced by the inclusion of a confirmation step. Parameters
that give higher sensitivity but lower specificity may be chosen when Sanger confirmation
testing will be performed (e.g., for targeted testing and primary findings of ES/GS).
However, thresholds with higher specificity are recommended for calling variants that may
be included in incidental findings without confirmation. It is recommended to analyze the
performance of different types of variants separately because their performance may vary.
For example, coverage and allelic fraction for in/dels can be lower when the alignment tool
discards in/del-containing reads.
Additional metrics that may be helpful for determining data quality include the percentage
of reads aligned to the human genome, the percentage of reads that are unique (before
removal of duplicates), the percentage of bases corresponding to targeted sequences, the
uniformity of coverage, and the percentage of targeted bases with no coverage.
E.3. Determination of performance parameters
The validation process should document: (i) analytical sensitivity and FN rate, (ii) analytical
specificity and FP rate, (iii) predicted clinical sensitivity, and (iv) assay robustness and
reproducibility. Parameters may be calculated at the technology level initially; however, if
multiple technologies are used in the test, the final reported parameters should be relevant to
the full protocol of the test. For example, tests may include both NGS and companion
technologies including steps to confirm variants and/or fill in missing data. The final
analytical parameters of a test must reflect the entire testing process.
E.3.1. Analytical sensitivity—Current American College of Medical Genetics and
Genomics (ACMG) guidelines often define analytical sensitivity as the “proportion of
biological samples that have a positive test result or known mutation and that are correctly
classified as positive” but also state that this concept does not fit tests that use genome
scanning methods where novel, unclassified variants can be detected (http://www.acmg.net;
Standards and Guidelines for Clinical Genetic Laboratories 2008 Edition, section C8.4).
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These tests therefore require a dual approach. For a given test, the laboratory must document
that the NGS assay can correctly identify known disease-causing variants, particularly if
they are common in the tested population. To project the analytical sensitivity for detecting
novel variants, it is necessary to extrapolate from the analysis of known variants to the entire
region analyzed. Here, it is important to maximize the number of variants tested as well as
the genomic regions they represent and calculate confidence intervals. An online tool for
calculating confidence intervals can be found at http://www.pedro.org.au/english/
downloads/confidence-interval-calculator/. It is recommended that a separate calculation be
performed for each variant type that is relevant for the clinical context in which testing is
offered (e.g., substitutions, in/dels, CNVs). It is well known that detectability of variants can
be influenced by local sequence context, and therefore a high general sensitivity may not
always be true for every possible variant. However, the higher the number of variants tested
and the larger and more diverse the genomic loci included in this cumulative analysis, the
higher the confidence that the established sensitivity can be accurately extrapolated
(Mattocks et al. 2010). The variants included in this type of analysis do not have to be
pathogenic because this has no bearing on their detectability.
E.3.2. Analytical specificity—Current ACMG guidelines define analytical specificity as
“the proportion of biological samples that have a negative test result or no identified
mutation (being tested for) and that are correctly classified as negative” (http://
www.acmg.net; Standards and Guidelines for Clinical Genetic Laboratories 2008 Edition,
Section C8.4). Traditionally, “negative” is defined as the absence of a pathogenic variant;
however, for the reasons described above this is not a meaningful measure to define
analytical performance in sequencing tests. By contrast, it is most useful to calculate the
average FP rate per sample and then express this as number of FPs/interval tested (e.g., per
kb of sequence). This will inform an estimate of the number of FPs expected per sample for
a given test and will also allow an extrapolation for larger panels including the exome and
genome. If variant calls are confirmed by Sanger sequencing, the technology-specific FP
rate is less critical unless it generates an amount of confirmatory testing per sample that is
not sustainable for the laboratory.
E.3.3. FN and FP rates—The FN rate can be calculated as 1 – sensitivity.The FP rate can
be calculated as 1 – specificity.
E.3.4. Clinical sensitivity—For disease-specific targeted panels, the laboratory should
establish the estimated clinical sensitivity of the test on the basis of a combination of
analytical performance parameters and the known contribution of the targeted set of genes
and types of variants detectable for that disease. For ES and GS of patients with
undiagnosed disorders, it is not feasible to calculate a theoretical clinical sensitivity for the
test given its dependency on the applications and indications for testing. However, empirical
data from one recent study suggest that these tests have a clinical sensitivity of ~20% (Gahl
et al. 2012). Likewise, laboratories should track and share success rates across different
disease areas to aid in setting realistic expectations for the likelihood of an etiology being
detected for certain types of indications.
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E.3.5. Assay robustness—It is recommended that laboratories measure robustness
(likelihood of assay success) for the main assay components such as library preparation and
sequencing runs and have adequate Q/C measures in place to assess their success (see
section F.4).
E.3.6. Assay precision—It is recommended that the laboratory document the assay's
precision (repeatability and reproducibility) based upon known sources of variation. For
example, it is suggested that the laboratory take a single library or sample preparation and
run it on two or three lanes/wells within the same run (repeatability, within-run variability)
as well as on two or three different runs (reproducibility, between-run variability). Other
meaningful measures of reproducibility are instrument-to instrument variability (run samples
on two or three different instruments if available) and interoperator variability. Complete
concordance of results is unlikely for NGS technologies; however, the laboratory should
establish parameters for sufficient repeatability and reproducibility. For example, a range of
>95-98% has been used by some laboratories.
E.3.7. Limit of detection—It is recommended that laboratories determine the minimal
specimen requirements to generate enough DNA to complete the assay and any follow-up
analysis. In addition, if testing samples with mixed content (tumor, mitochondrial, mosaic,
etc.), the laboratory must determine the lower limit of detection of variants based on dilution
assays, mixing two pure samples at variable percentages. This value should be used in
providing a lower limit of detection for likely mixed specimens as well as acceptance
criteria for tumor specimens with assessed tumor percentage.
E.4. Validating modified components of a test or platform
E.4.1. Modified assay conditions, reagents, instruments, and analytical pipelines
Because NGS is a dynamic technology, suppliers are continually improving the chemistries.
Laboratories must validate any changes to the existing test (e.g., new sequencing chemistry,
new instrument, new lot of capture reagents, new software versions) using an end-toend test
validation with previously analyzed specimens or well-characterized controls. It is
recommended to always include the same, renewable, well-characterized sample (e.g., a
HapMap sample) and determine analytical performance parameters and other parameters,
such as coverage, as outlined in the prior sections.
E.4.2. Added/modified test content
When adding new genes to an established targeted panel, the laboratory should analyze a
small number of samples and establish that the performance of the test for analyzing the
existing genes has not been altered and that the performance for analyzing the new genes is
acceptable.
The above-described changes should be reviewed by the laboratory director. Separate
documentation should be generated, and the date of introduction of the new version into the
pipeline for clinical samples should be documented.
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Monitoring preanalytical variables, analytical variables, and postanalytical variables should
be part of the laboratory's quality assurance (Q/A) and quality improvement programs. Such
variables may include quality of the specimen received, number of NGS run failures, and
variant detection parameters.
F.1. Specimen requirements
NGS may be performed on any specimen that yields DNA (e.g., peripheral blood, fresh or
frozen tissues, paraffin-embedded tissues, prenatal specimens). The laboratory needs to
establish the types of specimens (which may include acceptance of genomic DNA as a
sample type) and minimum required quantities appropriate for NGS assays. The quality of
DNA and variant detection requirements will likely differ for some specimen types, and, as
such, the laboratory will need to determine acceptable parameters for each sample type (e.g.,
volume, amount of tissue.
F.2. DNA requirements and processing
The laboratory should establish the minimum DNA requirements to perform the test.
Considerations include whether the test is performed once per specimen and how much
DNA may be required for confirmatory and follow-up procedures. The laboratory should
have written protocols in the laboratory procedure manual and/or quality management
program for DNA extraction and quantification (e.g., fluorometry, spectrophotometry) for
obtaining an adequate quality and concentration of DNA. The laboratory should have
documentation of these parameters in each patient record.
F.3. Suboptimal samples
If a sample does not meet requirements of the laboratory and is deemed suboptimal, the
recommended action is to reject the specimen and request a new specimen. If obtaining a
new specimen is not possible, whole-genome amplification could be considered if the
laboratory is experienced in this technique. In this case, the potential biases inherent in the
technique (e.g., uneven or incomplete amplification of the entire genome) should be detailed
in the report so that the physician and patient are informed of the limitations of this
technique. Written standards describing when and how the whole-genome amplification
procedure is performed should be incorporated into the laboratory manual.
F.4. Quality control and quality assurance
A Q/A program used by the laboratory is expected to support the routine analysis of samples
and the interpretation and reporting of NGS data. Laboratories should put in place
predetermined Q/C checkpoints for monitoring Q/A. The Q/A program should also include
documentation of which instruments are used in each test and documentation of all reagent
lot numbers. Laboratories are expected to document any deviation from the standard
procedures established by the laboratory during the validation process.
F.4.1. General quality control—The development of Q/C stops during the workflow is
essential for any clinical laboratory test and of critical importance for many NGS platforms,
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because assays can be lengthy and expensive and identification of samples that have a high
probability of generating results of unacceptable quality is important to ensure optimal
turnaround times. However, due to the high diversity of NGS platforms and assays, specific
Q/C measures may vary. Similar to Sanger-based sequencing, positive controls do not need
to be tested concurrent with routine clinical tests (Maddalena et al. 2005); however, the
operating procedure must have methods to evaluate and control for possible contamination
at various points in the procedure. Generally, Q/C stops need to be added to the wet-
laboratory process before the sequencing run, to the sequencing run itself and at the end of
the sequencing run before executing data analysis. Examples of Q/C stops include
determining the success of initial DNA fragmentation (incompletely sheared gDNA will
result in suboptimal data), monitoring error rates during the sequencing run (enabling
abortion of the run if there is a problem) and postrun/preanalysis assessment of the read
quality (e.g., percentage of bases above a predetermined quality threshold, Q/C alignments).
F.4.2. Bioinformatics—A Q/A program for the bioinformatics process or pipeline should
be developed to support the analysis, interpretation, and reporting of NGS data. The Q/A
program should also document corrective measures that have been put in place by the
laboratory to report and resolve any deviation from the developed pipeline during the testing
process.
The laboratory must also document the bioinformatics pipeline that it uses in the analysis of
NGS data and capture the specific version of each component of the pipeline utilized in the
analysis of each patient test. A system must be developed that allows the laboratory to track
software versions, the specific changes each version incorporates, and the date the new
version was implemented on clinical samples. The Q/A program should be developed to
include the description of input and output files for each step of the process and metrics and
Q/C parameters for optimal performance.
F.5. Staff qualifications
Given the technical and interpretive complexity of NGS, we recommend that the reporting
and oversight of clinical NGS-based testing be performed by individuals with appropriate
professional training and certification (American Board of Medical Genetics-certified
medical/laboratory geneticists or American Board of Pathology-certified molecular genetic
pathologists) and with extensive experience in the evaluation of sequence variation and
evidence for disease causation as well as technical expertise in sequencing technologies. For
laboratories offering ES or GS services, the laboratory should have access to broad clinical
genetics expertise for evaluating the relationships between genes, variation, and disease
phenotypes.
F.6. Data storage and traceability of patient reports
NGS generates a massive amount of data, and laboratories may choose to store the data in-
house or offsite. Cloud computing is also becoming a widely available choice for data
analysis and storage. However, many cloud computing environments are not Health
Insurance Portability and Accountability Act compliant and therefore laboratories must
ensure that the method used for data storage is compliant with the Act and allows
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traceability of patient data. Due to the multistep nature of NGS informatics analysis, files
with differing information contents and sizes will be generated. Generally, NGS sequencing
image files, which can be several terabytes in size, are not stored. Laboratories may employ
widely heterogeneous sequence alignment and variant calling algorithms; thus, the types of
files generated in the process of NGS will differ greatly between laboratories. Laboratories
should make explicit in their policies which file types and what length of time each type will
be retained, and the data retention policy must be in accordance with local, state, and federal
requirements. CLIA regulations (section 493.1105) require storage of analytic systems
records and test reports for at least 2 years. For more specific suggestions for NGS
technologies, we recommend that the laboratory consider a minimum of 2-year storage of a
file type that would allow regeneration of the primary results as well as reanalysis with
improved analytic pipelines (e.g., bam or fastq files with all reads retained). In addition,
laboratories should consider retention of the VCF, along with the final clinical test report
interpreting the subset of clinically relevant variants, for as long as possible, given the
likelihood of a future request for reinterpretation of variant significance.
F.7. Reference materials
Reference materials (RM) are used by clinical laboratories for test validation, Q/C, and
proficiency testing (PT). The goal for NGS applications is to have genome-wide-
characterized RMs for sequence and CNVs. This is important because no single clinical-
grade reference sequence exists today. However, several human cell lines available from
Coriell Repositories (e.g., NS12911; Levy et al. 2007) have had GS performed with
published results.
The Centers for Disease Control and Prevention (http://www.cdc.gov/clia/Resources/
GetRM) and the National Institute for Standards and Technology have efforts to more fully
characterize several of the Coriell samples by organizing laboratories performing gene
panel, ES, or GS, and copy-number variation analysis. Depth of coverage and consensus
between laboratories and platforms will be recorded, so laboratories will know which areas
of the genome are highly characterized and which do not yet have consensus. However, if
cell lines are used as RM, genomic stability over time will be a concern. Studies including
sequencing different passages will be necessary to understand the extent to which instability
will affect the use of cell lines for NGS. In addition, several other organizations such as the
College of American Pathologists, and the US Food and Drug Administration also have
efforts to define RMs for use in evaluating instrumentation and test performance.
Genomic DNA extracted from blood is stable, but gathering enough from one individual for
long-term, potentially multi-laboratory use is challenging. Still, it could be possible to have
large quantities of several samples that could be used for years via whole-genome
amplification.
Simulated electronic sequences created through computational methods may also be useful,
and could be incorporated into Q/C or PT processes. Simulated sequences are typically
designed to focus on a specific region to address a specific issue, such as repetitive
sequences, known in/dels, and SNPs.
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CLIA requirements for PT or alternative assessments pose challenges for NGS. Typically,
PT/alternative assessments are performed twice yearly for each clinically offered assay. For
NGS, the definition of the assay may be a gene panel, exome analysis, or genome analysis.
A formal proficiency challenge available for single-gene disorders from the Biochemical
and Molecular Resource Committee (a joint committee of the College of American
Pathologists and the ACMG) typically has two PT challenges yearly, each consisting of
three samples. The current cost of performing a gene panel, ES, or GS assay on six PT
samples per year may not be financially feasible for most clinical laboratories. Therefore,
other models are being explored, such as methods-based (technical wet laboratory) or
analytical (informatics) challenges. The College of American Pathologists/ACMG
Sequencing survey currently involves a Sanger-sequencing challenge in which electronic
files of sequences and references are sent to participants to assess their ability to align,
detect, properly name, and interpret sequence variants in any gene. A similar challenge
could be used for the informatics portion of an NGS assay. The College of American
Pathologists released a laboratory checklist for NGS in July 2012 and is currently
implementing a pilot PT program for NGS which is expected to be available in widely in
2014. The European quality network has launched a pilot PT program that is also available
to US laboratories. However, until PT services for NGS/ES/GS are fully available
laboratories are required to employ existing acceptable PT approaches according to CLIA
guidelines using national programs if available, interlaboratory exchange if no national




The laboratory should have written standards for NGS test prioritization and turnaround
times that are based on the indication for testing. These turnaround times should be
clinically appropriate.
G.2. Data interpretation
Each variant identified in a disease-targeted test should be evaluated and classified
according to ACMG guidelines (Richards et al. 2008). This should include an evidence-
based assessment of the likelihood that the variant disrupts the function of the gene or gene
product as well as its potential role in disease. For tests that cover a broad range of
phenotypes, as well as for reporting results from ES and GS tests, in addition to evaluating
whether the variant likely alters gene or protein function, the assessment should also
evaluate whether the known phenotypes associated with gene disruption match the patient's
phenotype. If multiple variants of potential clinical significance are identified, the
interpretation should discuss the likely relevance of each variant to the patient's phenotype
and prioritize variants accordingly.
For ES/GS reporting, it is at the discretion of the laboratory to decide whether to report
variants in genes without any known disease association. If the laboratory accepts patients
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who have tested negative for existing disease-targeted tests, the laboratory should have a
plan in place for how it will evaluate variants in genes without a known disease association.
Patients should not be expected to bear the costs of research-grade analyses, and any results
that are gained from these analyses should be presented as preliminary findings until
evidence can be garnered that definitively supports the association of that gene with a
human clinical phenotype.
Laboratories are also strongly encouraged to deposit data from clinical sequencing into
public databases such as ClinVar (http://www.ncbi.nlm.nih.gov/clinvar), in order to more
rapidly build knowledge that will lead to improved care.
G.3. Reporting of incidental findings
As an inevitable consequence of ES/GS testing, sequence information will be generated that
is not immediately germane to the diagnostic intent of the test. Such incidental findings may
or may not have clinical implications for a given patient, and some patients may not desire
the return of such information. Variants of uncertain significance (VUSs) that are discovered
as incidental findings in genes unrelated to the diagnostic evaluation should not be returned
because they have no clear clinical implications and are more likely to cause confusion or
harm. However, certain types of incidental findings may be deemed sufficiently “medically
actionable” such that their return would be strongly encouraged. Therefore, it is
recommended that the laboratory carefully develop a policy and process for returning such
information and ensure that it conforms to accepted medical and ethical obligations as well
as additional practice policies that will continually develop in this area. The laboratory
should provide the following information about incidental findings: (i) whether it will
systematically search for, and report on, certain findings, as set forth in the recent ACMG
Recommendations for reporting of Incidental Findings in Clinical Exome and Genome
Sequencing (Green et al, 2013) or whether it will only report variants that are uncovered
unintentionally; (ii) whether incidental findings are routinely confirmed to ensure analytic
accuracy or whether confirmation is recommended through additional follow-up testing (see
section D.6); (iii) a clear definition of the criteria used to decide what types of incidental
findings to report; and (iv) clear instructions on how all, or certain types of, incidental
findings can be requested and whether and how they can be declined.
In this way, the ordering provider will be aware of the potential scope of incidental findings
before ordering ES/GS testing and can ensure that informed consent and shared decision
making with the patient includes a discussion of how incidental findings will be handled.
Any return of incidental findings should be done in collaboration with the ordering provider
to ensure that those results are interpreted in the context of the patient's medical and family
history and personal desires for receiving incidental results. Additional details on the return
of incidental findings are outside the scope of this document but are available in a separate
set of ACMG Recommendations (Green et al, 2013).
G.4. Written report
All NGS reports must include a list of variants identified, annotated according to HGVS
nomenclature (http://www.hgvs.org) and clinically classified according to ACMG guidelines
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(Richards et al. 2008). These guidelines are updated regularly, and the laboratory should
review these guidelines carefully. Gene names should adhere to the approved HUGO Gene
Nomenclature Committee nomenclature (http://www.genenames.org). An example data
structure is shown: MYBPC3 (NM_000256.3), heterozygous c.1504C>T (p.Arg502Trp),
exon 17, pathogenic.
The transcript being used for providing c. and p. nomenclature and exon numbering should
be provided in the report, either with the variant as noted above, in the methodology, or
through a referenced Internet-accessible website. If a variant has a different nomenclature
across different transcripts relevant to the indication for testing, the variant should be
reported according to the major transcript unless a different, and potentially greater, impact
is predicted for another transcript. In the latter case, both impacts should be described in the
report.
It is recommended that for reporting the primary findings in a targeted diagnostic test, a
succinct, high-level interpretive result should be provided at the start of the interpretation
consisting of findings that are “positive” (detection of a mutation that explains a patient's
condition), “negative” (no variants identified of likely relevance to the diagnostic
indication), or “inconclusive” (a clear explanation of the patient's condition was not found
either due to only variants of unknown significance being identified or due to only a single
heterozygous variant identified for a recessive condition). Other overall result interpretations
may be appropriate for certain indications such as “carrier” for recessive carrier screening
tests. Additional one-line explanations can be added as noted in the sample reports (see
Supplementary Data online). It is also recommended that variants be listed according to
their relevance to the patient's indication for testing.
Laboratories should document the supporting evidence used to classify variants with respect
to their known or potential role in disease. It is at the discretion of the laboratory to report
variants classified as “likely benign” or “benign.” Laboratories must document a clear policy
for determining what variants are excluded from reports in both material provided to
ordering providers and on the patient's individual report. For targeted NGS tests, if likely
benign or benign variants are included, they should be clearly delineated from variants with
known or more likely clinical relevance (e.g., pathogenic and VUSs). Laboratories may also
wish to separate variants with known or assumed pathogenicity from VUSs. For genomic
and exomic sequencing, VUSs should be reported if found in genes relevant to the primary
indication for testing but should not be reported if found in genes outside those relevant to
the primary indication for testing as described in the preceding section on the reporting of
incidental findings.
It is recommended that laboratories report variant data in structured format, according to
evolving health-care information technology standards. Current standards have been
developed for HL7 messaging and dictate a structure for variant reporting (HL7 version 2
Implementation Guide: Clinical Genomics at http://www.hl7.org/implement/standards). The
variant elements should include gene name, zygosity, cDNA nomenclature, protein
nomenclature, exon number, and clinical assertion as noted above. This structure enables
deposition of variants into the electronic health record, which in turn enables clinical
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decision-support algorithms to be leveraged for effective use of genetic information in
health care. However, it is currently recommended that genetic data entering the electronic
health record environment be restricted to those results relevant to the indication for testing
and incidental findings with evidence of both analytical and clinical validity.
For targeted NGS tests, the report should contain a summary of the genes analyzed, and if
full coverage is not guaranteed for all genes, then actual coverage achieved across the
targeted region must be provided in each patient report. It should be noted that complete
coverage of all high-yield genes, using Sanger sequencing to fill in missing regions, is
strongly recommended. In addition, for negative test results from targeted analyses, the
diagnostic yield (empiric or predicted) of the panel of genes analyzed should be provided to
assist in determining the clinical sensitivity of the test. The laboratory should also report any
limitations in analysis for specific variant types (such as CNVs) if the method of analysis
does not include all variant types.
For ES/GS testing, a description of the process of data analysis should be provided in the
report, whether the result is positive, negative, or inconclusive. Technical parameters
regarding the level of coverage of the exome or genome should be provided. For GS, in
addition to genome coverage, a separate coverage value for gene coding regions should be
provided. In addition, if the laboratory is asked to perform analysis for a phenotype with one
or more established causative genes, the gene coverage should be reported as well as any
additional limitations related to the analytical detection of reported variants for the provided
phenotype.
If parents or other family members are tested to assist with the interpretation of the variants
found in the proband (e.g., submission of a trio of samples), only the minimal amount of
information required to interpret the variants and comply with Health Insurance Portability
and Accountability Act regulations should be provided in the proband's report. Specific
names and relationships should be avoided if possible. As an example, the following
statements would be appropriate: “Parental studies demonstrate that the variants are on
separate copies of the gene, with one inherited from each parent.” “Segregation studies
showed consistent inheritance of the variant with the disease in three additional affected
family members.”
Sample reports are included as examples of some ways to provide the content recommended
above (see Supplementary Data online). Additional details in these sample reports are
provided as examples only, and such details are ultimately left to the discretion of the
laboratory director. However, reports must be clear and concise with the clinical
significance of any relevant findings clearly stated and comprehensible for all varieties of
health-care providers.
G.5. Data reanalysis
As the content of sequencing tests expands and the number of variants identified grows,
expanding to thousands and millions of variants from ES and GS, the ability for laboratories
to update reports as variant knowledge changes will be untenable without appropriate
mechanisms and resources to sustain those updates. To set appropriate expectations with
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physicians and patients, laboratories should provide clear policies on the reanalysis of data
from genetic testing and whether additional charges may apply for reanalysis.
For reports containing VUSs related to the primary indication and in the absence of updates
that may be proactively provided by the laboratory, it is recommended that laboratories
suggest periodic inquiry by physicians to determine if knowledge has changed on any VUSs
including variants reported as “likely pathogenic.” Please see ACMG guidelines on duty to
re-contact regarding physician responsibility (Hirschhorn et al. 1999).
H. SUMMARY
Identifying disease etiologies for genetic conditions with substantial genetic heterogeneity
has been a long-standing and challenging diagnostic hurdle. NGS overcomes many of the
scalability obstacles for large-scale sequencing of DNA that have been faced by clinical
laboratories utilizing traditional Sanger methods. However, along with the capability to
produce high-quality sequence data for applications ranging from clinically relevant targeted
panels to the whole genome, NGS brings new technical challenges that must be appreciated
and logically addressed. This first version of the ACMG Clinical Laboratory Standards for
Next-Generation Sequencing covers a broad spectrum of topics for those already offering
diagnostic testing based on this technology as well as those considering their options for
how to enter this arena. Most of the topics should be familiar to this audience but are
discussed in some detail given the many unique circumstances and demands of NGS.
Although key aspects of the clinical implementation of NGS technology have been
addressed, additional recommendations regarding specific applications of the technology
may be needed in the future. As always, the diagnostic community will collectively benefit
by discussing the newest and most pressing NGS issues together. This will require an
ongoing dialogue among those already engaged in this pursuit, those determining how to
become involved in this new paradigm of molecular testing, and those who will be
responsible for ordering and communicating NGS results to patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Next-generation sequencing involves three major components: sample preparation,
sequencing, and data analysis.
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Next-generation sequencing test development and validation process. CNV, copy-number
variant; in/dels, insertions and deletions; sample prep, sample preparation.
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